"""
Question: 1101 

Evidence: The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients. Due to the confidential nature of population level HIV sequence data sets and the criminalization of HIV transmission in Canada, the HIV sequences and associated meta data will not be made publicly available.

Rationale: The paper analyzes a large, confidential BC-CfE dataset that is not publicly available and has not been previously released with accession numbers, indicating it reports new analyses of previously unpublished sequence data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: 9,822 HIV pol sequences collected during routine drug resistance genotyping were used alongside simulated sequence data to infer sets of phylogenetic transmission clusters via patristic distance threshold. The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients.

Rationale: The paper explicitly states it used thousands of HIV pol sequences from clinical genotyping for phylogenetic analyses.

Answer: Yes
"""

"""
Question: 1103 

Evidence: Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs). Simulation was performed using the FAVITES framework to create a contact network, seed infected individuals, generate transmission events and the viral evolution between them, and subsequently sample viral sequences.

Rationale: The methods describe observational clinical sequencing and computational simulations but do not mention any laboratory in vitro passage of viruses.

Answer: No
"""

"""
Question: 1104 

Evidence: Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs). Known SDRM codons were masked before inference of a distribution of 100 phylogenetic tree replicates.

Rationale: The study uses genotypic data and masks resistance sites for phylogenetic analysis; it does not perform phenotypic susceptibility testing or report new in vitro susceptibility results.

Answer: No
"""

"""
Question: 2101 

Evidence: The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients. Due to the confidential nature of population level HIV sequence data sets and the criminalization of HIV transmission in Canada, the HIV sequences and associated meta data will not be made publicly available.

Rationale: The paper states sequences will not be made publicly available, and it does not provide GenBank accession numbers.

Answer: No
"""

"""
Question: 2102 

Evidence: The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients. Due to the confidential nature of population level HIV sequence data sets and the criminalization of HIV transmission in Canada, the HIV sequences and associated meta data will not be made publicly available.

Rationale: No accession numbers are provided for any clinical isolates; the dataset is confidential and not deposited.

Answer: No
"""

"""
Question: 2103 

Evidence: The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients. Due to the confidential nature of population level HIV sequence data sets and the criminalization of HIV transmission in Canada, the HIV sequences and associated meta data will not be made publicly available.

Rationale: Because the sequences are not publicly available, no GenBank accession numbers are reported.

Answer: NA
"""

"""
Question: 2202 

Evidence: Known SDRM codons were masked before inference of a distribution of 100 phylogenetic tree replicates. All data were doubly de-identified prior to analysis.

Rationale: The study does not present per-isolate mutation listings; instead, resistance sites were masked for phylogenetic analysis and no individual mutation tables are reported.

Answer: No
"""

"""
Question: 2301 

Evidence: Current methods of HIV-1 outbreak management in countries with sufficient resources and government support to sustain continuous monitoring are highly effective. Phylogenetic monitoring of HIV-1 transmission is highly amenable because viral populations are known to diverge following transmission due to the rapid rate of evolution of HIV and host-specific selection.

Rationale: The paper repeatedly refers to HIV-1 in its background and focus.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients. Phylogenetic monitoring of HIV-1 transmission is highly amenable because viral populations are known to diverge following transmission due to the rapid rate of evolution of HIV and host-specific selection.

Rationale: The paper does not report any subtype information for the sequenced viruses.

Answer: NA
"""

"""
Question: 2303 

Evidence: The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients. All 35 752 anonymized sequences were aligned with MAFFT v7.310.

Rationale: The study explicitly states that partial pol sequences were used.

Answer: pol (partial pol)
"""

"""
Question: 2304 

Evidence: 9,822 HIV pol sequences collected during routine drug resistance genotyping were used alongside simulated sequence data to infer sets of phylogenetic transmission clusters via patristic distance threshold. The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients.

Rationale: The paper analyzes and reports results obtained from HIV pol sequences.

Answer: Yes
"""

"""
Question: 2401 

Evidence: In British Columbia (BC), Canada, near real-time phylogenetic monitoring has been employed since 2013 to detect and prioritize groups with the highest risk of transmission for focused intervention. The BC-CfE retains both the HIV sequence data and associated metadata.

Rationale: The sequences analyzed are from British Columbia, Canada, through the BC Centre for Excellence in HIV/AIDS.

Answer: British Columbia, Canada
"""

"""
Question: 2402 

Evidence: The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients. The full trees were pruned using the ape R package to create 10 subtrees containing the sequences sampled by the end of each year in the 2009--2018 period.

Rationale: Samples were obtained from 1996–2018, with analytic subtrees constructed for 2009–2018.

Answer: 1996–2018 (analytic subtrees for 2009–2018)
"""

"""
Question: 2502 

Evidence: In BC, routine clinical care following every new HIV diagnosis includes drug resistance genotype testing performed by the BC Centre for Excellence in HIV/AIDS (BC-CfE). Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs).

Rationale: The paper does not specify the sequencing platform (e.g., Sanger) used for genotyping.

Answer: NA
"""

"""
Question: 2503 

Evidence: In BC, routine clinical care following every new HIV diagnosis includes drug resistance genotype testing performed by the BC Centre for Excellence in HIV/AIDS (BC-CfE). Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs).

Rationale: The paper does not indicate that next-generation sequencing was used; the sequencing technology is not specified.

Answer: NA
"""

"""
Question: 2504 

Evidence: In BC, routine clinical care following every new HIV diagnosis includes drug resistance genotype testing performed by the BC Centre for Excellence in HIV/AIDS (BC-CfE). All data were doubly de-identified prior to analysis.

Rationale: There is no mention of cloning of samples prior to sequencing.

Answer: NA
"""

"""
Question: 2505 

Evidence: In BC, routine clinical care following every new HIV diagnosis includes drug resistance genotype testing performed by the BC Centre for Excellence in HIV/AIDS (BC-CfE). Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs).

Rationale: The paper does not report single genome sequencing.

Answer: NA
"""

"""
Question: 2506 

Evidence: In BC, routine clinical care following every new HIV diagnosis includes drug resistance genotype testing performed by the BC Centre for Excellence in HIV/AIDS (BC-CfE). All data were doubly de-identified prior to analysis.

Rationale: The study does not report molecular cloning.

Answer: NA
"""

"""
Question: 2601 

Evidence: Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs). The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients.

Rationale: Viral RNA from blood (plasma) indicates plasma-based sequencing results were used.

Answer: Yes
"""

"""
Question: 2602 

Evidence: Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs). The study focuses on sequences derived from routine drug resistance genotyping and does not mention PBMC-derived sequences.

Rationale: Only plasma RNA-based sequencing is described; PBMC sequencing is not reported.

Answer: No
"""

"""
Question: 2603 

Evidence: Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs). The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients.

Rationale: All reported sequences originate from plasma RNA-based genotyping; the total number of sequences is 35,752.

Answer: 35,752
"""

"""
Question: 2604 

Evidence: Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs). The study dataset description does not mention PBMC-derived sequencing.

Rationale: The paper does not report any PBMC sequencing counts.

Answer: NA
"""

"""
Question: 2605 

Evidence: Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs). All data were doubly de-identified prior to analysis.

Rationale: While plasma RNA suggests active viremia, the paper does not explicitly state replication status of individuals at sampling.

Answer: NA
"""

"""
Question: 2606 

Evidence: Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs). The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients.

Rationale: Sequencing was performed on viral RNA rather than proviral DNA; no proviral DNA reservoir sequencing is reported.

Answer: No
"""

"""
Question: 2701 

Evidence: In BC, routine clinical care following every new HIV diagnosis includes drug resistance genotype testing performed by the BC Centre for Excellence in HIV/AIDS (BC-CfE). All data were doubly de-identified prior to analysis.

Rationale: The paper does not specify age groups such as infants or children.

Answer: NA
"""

"""
Question: 2702 

Evidence: In BC, routine clinical care following every new HIV diagnosis includes drug resistance genotype testing performed by the BC Centre for Excellence in HIV/AIDS (BC-CfE). The University of British Columbia—Providence Health Care Research Ethics Board granted ethical approval for this study (H07-02559).

Rationale: The sequences were obtained as part of routine clinical care, not a clinical trial, and no trial participation is mentioned.

Answer: NA
"""

"""
Question: 2703 

Evidence: In BC, routine clinical care following every new HIV diagnosis includes drug resistance genotype testing performed by the BC Centre for Excellence in HIV/AIDS (BC-CfE). The University of British Columbia—Providence Health Care Research Ethics Board granted ethical approval for this study (H07-02559).

Rationale: There is no indication the cohort was a clinical trial; thus whether all were in a trial cannot be determined.

Answer: NA
"""

"""
Question: 3101 

Evidence: The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients. All 35 752 anonymized sequences were aligned with MAFFT v7.310.

Rationale: The dataset includes sequences from 9,822 patients.

Answer: 9,822
"""

"""
Question: 3102 

Evidence: The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive, totalling 35 752 partial pol HIV sequences derived from viruses sampled from 9822 patients. All 35 752 anonymized sequences were aligned with MAFFT v7.310.

Rationale: Every individual included in the dataset had sequences, as the dataset is defined by the presence of sequences.

Answer: Yes
"""

"""
Question: 4101 

Evidence: Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs). All data were doubly de-identified prior to analysis.

Rationale: The paper does not stratify sequences by ART-naive status.

Answer: NA
"""

"""
Question: 4102 

Evidence: Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs). All data were doubly de-identified prior to analysis.

Rationale: The paper does not indicate whether sequences were from ART-experienced individuals.

Answer: NA
"""

"""
Question: 4103 

Evidence: Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs). All data were doubly de-identified prior to analysis.

Rationale: The study does not report ART status, so it is unknown whether both naive and experienced individuals were included.

Answer: NA
"""

"""
Question: 4104 

Evidence: Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs). The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive.

Rationale: No counts by ART-naive status are provided.

Answer: NA
"""

"""
Question: 4105 

Evidence: The BC-CfE retains both the HIV sequence data and associated metadata. All data were doubly de-identified prior to analysis.

Rationale: Although metadata exist, the paper does not provide complete ART history information for all individuals.

Answer: No
"""

"""
Question: 4201 

Evidence: Known SDRM codons were masked before inference of a distribution of 100 phylogenetic tree replicates. The addition of quantitative measures such as cluster size, previous cluster growth or mean cluster viral load can make the prioritization procedure less subjective.

Rationale: Masking SDRM codons and focus on phylogenetic metrics indicates the paper does not report prevalence of transmitted drug resistance.

Answer: No
"""

"""
Question: 4202 

Evidence: Known SDRM codons were masked before inference of a distribution of 100 phylogenetic tree replicates. We demonstrate that phylogenetic approximations of transmission derived from viral sequence data offer advantages over other common methods of prioritizing clusters, while meeting and frequently exceeding existing performance standards.

Rationale: The study does not estimate pretreatment resistance prevalence; resistance positions were masked for phylogenetics.

Answer: No
"""

"""
Question: 4301 

Evidence: Linkage or re-linkage to care can help begin or improve adherence to ART, optimize ART regimen choices, and encourage consistent viral load suppression. Both cluster members and their contacts can be encouraged to maintain safe practices regarding their risk behaviours.

Rationale: The paper discusses ART in general but does not report specific drug classes received by individuals.

Answer: NA
"""

"""
Question: 4302 

Evidence: Linkage or re-linkage to care can help begin or improve adherence to ART, optimize ART regimen choices, and encourage consistent viral load suppression. However, there are no established cutoffs defining when such measures reach a level warranting rapid intervention.

Rationale: No information is provided about integrase inhibitor receipt.

Answer: No
"""

"""
Question: 4303 

Evidence: Linkage or re-linkage to care can help begin or improve adherence to ART, optimize ART regimen choices, and encourage consistent viral load suppression. However, there are no established cutoffs defining when such measures reach a level warranting rapid intervention.

Rationale: The paper does not report whether individuals received protease inhibitors.

Answer: No
"""

"""
Question: 4304 

Evidence: Linkage or re-linkage to care can help begin or improve adherence to ART, optimize ART regimen choices, and encourage consistent viral load suppression. The study focuses on prioritization measures rather than detailed treatment regimens.

Rationale: The paper does not provide regimen-level details, so whether all received the same ART cannot be determined.

Answer: NA
"""

"""
Question: 4305 

Evidence: The study dataset was restricted to data collected by the BC-CfE between May 1996 and December 2018 inclusive. The paper does not describe individual treatment histories or drug classes received.

Rationale: INSTI exposure status is not reported.

Answer: NA
"""

"""
Question: 4403 

Evidence: The study focuses on phylogenetic prioritization using routine genotyping data and simulations. Individual ART regimen histories are not described.

Rationale: The number of individuals receiving more than one ART regimen is not provided.

Answer: NA
"""

"""
Question: 4404 

Evidence: The study focuses on phylogenetic prioritization using routine genotyping data and simulations. Individual ART regimen histories are not described.

Rationale: The number of individuals receiving more than two ART regimens is not provided.

Answer: NA
"""

"""
Question: 4405 

Evidence: The study focuses on phylogenetic prioritization using routine genotyping data and simulations. Individual ART regimen histories are not described.

Rationale: It is not reported whether all individuals received the same number of ART regimens.

Answer: NA
"""

"""
Question: 4406 

Evidence: The study focuses on phylogenetic prioritization using routine genotyping data and simulations. Individual ART regimen histories are not described.

Rationale: It is not reported whether all individuals received one ART regimen.

Answer: NA
"""

"""
Question: 4501 

Evidence: The study focuses on phylogenetic prioritization using routine genotyping data and does not enumerate specific antiretroviral drugs received by individuals. All data were doubly de-identified prior to analysis.

Rationale: The number of individuals who received dolutegravir is not reported.

Answer: NA
"""

"""
Question: 4502 

Evidence: The study focuses on phylogenetic prioritization using routine genotyping data and does not enumerate specific antiretroviral drugs received by individuals. All data were doubly de-identified prior to analysis.

Rationale: The number of individuals who received darunavir is not reported.

Answer: NA
"""

"""
Question: 5101 

Evidence: Known SDRM codons were masked before inference of a distribution of 100 phylogenetic tree replicates. The study focuses on phylogenetic diversification rate-based measures and growth-based measures rather than resistance prevalence.

Rationale: The paper does not report counts of individuals with resistance mutations.

Answer: NA
"""

"""
Question: 5102 

Evidence: Known SDRM codons were masked before inference of a distribution of 100 phylogenetic tree replicates. The study does not analyze or report specific resistance mutation frequencies.

Rationale: No counts of INSTI resistance mutations are provided.

Answer: NA
"""

"""
Question: 5103 

Evidence: Known SDRM codons were masked before inference of a distribution of 100 phylogenetic tree replicates. The study focuses on prioritization metrics, not mutation prevalence by drug.

Rationale: No counts of TDF resistance mutations are provided.

Answer: NA
"""

"""
Question: 5104 

Evidence: Known SDRM codons were masked before inference of a distribution of 100 phylogenetic tree replicates. The study does not report specific resistance mutations identified in individuals.

Rationale: No specific INSTI-resistance mutations are reported.

Answer: NA
"""

"""
Question: 6101 

Evidence: The addition of quantitative measures such as cluster size, previous cluster growth or mean cluster viral load can make the prioritization procedure less subjective. In this study, we employ both empirical and simulated data to evaluate the hypothesis that cluster prioritization measures based on phylogenetically derived lineage-level diversification rates will perform at least equally as well as commonly used non-phylogenetic growth-based prioritization measures.

Rationale: The paper does not perform or describe any phenotypic susceptibility testing.

Answer: NA
"""

"""
Question: 6102 

Evidence: The study employs phylogenetic and growth-based prioritization metrics and simulations. There is no section describing laboratory susceptibility assays or IC measurements.

Rationale: The paper does not report IC50/IC90 values.

Answer: No
"""

"""
Question: 6103 

Evidence: The study employs phylogenetic and growth-based prioritization metrics and simulations. There is no section describing laboratory susceptibility assays or fold-change analyses.

Rationale: The paper does not report IC50 fold change values.

Answer: No
"""

"""
Question: 6104 

Evidence: The study focuses on phylogenetic analyses (e.g., MAFFT alignments, FastTree phylogenies) and epidemiological simulations. No phenotypic susceptibility assay methods are described.

Rationale: No phenotypic assay is used or named.

Answer: NA
"""

"""
Question: 6105 

Evidence: The paper centers on phylogenetic diversification rates and growth-based measures for prioritization. No replication capacity assays or results are presented.

Rationale: Replication capacity data are not reported.

Answer: No
"""

"""
Question: 6106 

Evidence: The study focuses on phylogenetic prioritization using sequence data and simulations rather than in vitro drug testing. No drug susceptibility testing is described.

Rationale: No phenotypic testing of drugs was performed, so no drugs were tested for susceptibility.

Answer: NA
"""

"""
Question: 7101 

Evidence: Simulation was performed using the FAVITES framework to create a contact network, seed infected individuals, generate transmission events and the viral evolution between them, and subsequently sample viral sequences. Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs).

Rationale: The study did not construct site-directed mutant viruses; it used clinical sequences and simulated data.

Answer: No
"""

"""
Question: 7102 

Evidence: Simulation was performed using the FAVITES framework to create a contact network, seed infected individuals, generate transmission events and the viral evolution between them, and subsequently sample viral sequences. Viral RNA extracted from patient blood samples is used to determine which antiretroviral drugs will be most effective for each individual based on observed viral surveillance drug resistance mutations (SDRMs).

Rationale: The paper does not report any in vitro passage experiments; analyses are based on clinical sequences and computational simulation.

Answer: No
"""